Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brigatinib consolidation in stage III ALK+ NSCLC
NCT05718297Phase 2Withdrawn
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- Jun 2024
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of brigatinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by ETOP IBCSG Partners Foundation. Primary endpoint: Progression-Free Survival at 48 months. Planned start Jun 2024; status: withdrawn.
02
Drugs
brigatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05718297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05718297.